A Phase I Study of PP-001 Eye Drops in Healthy Adult Volunteers

• Status: Active, not recruiting
• Trial end date: 2021-01-01
• Target enrollment: 0
• Participant gender: All

Summary

In this study, PP-001 eye drops are assessed for safety and tolerability in healthy, adult volunteers. PP-001 is a novel, anti-inflammatory small molecule that inhibits a specific enzyme (Dihydroorotate Dehydrogenase).

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Panoptes Pharma GmbH
• Treatments: Ophthalmic Solutions

Criteria

Inclusion Criteria:

• male or female healthy volunteers 18 - 64 years of age

• good general state of health and participants must not have a diagnosis of any eye disease that could effect the pharmacokinetics of PP-001

Exclusion Criteria:

• participation in other clinical trials within 30 days prior to dosing start (ocular and non-ocular clinical trials)

• pregnant or nursing patients

• regular use of any ocular agents within 60 days prior to start dosing